| Original language | English (US) |
|---|---|
| Pages (from-to) | 1094-1096 |
| Number of pages | 3 |
| Journal | Clinical Journal of the American Society of Nephrology |
| Volume | 16 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2021 |
ASJC Scopus subject areas
- Epidemiology
- Critical Care and Intensive Care Medicine
- Nephrology
- Transplantation
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Sodium-glucose cotransporter-2 inhibitors and the risk of abnormal serum potassium level. / Joseph Hwang, Y.; Lyu, Beini; Chang, Alex R.; Inker, Lesley A.; Grams, Morgan E.; Shin, Jung Im.
In: Clinical Journal of the American Society of Nephrology, Vol. 16, No. 7, 07.2021, p. 1094-1096.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Sodium-glucose cotransporter-2 inhibitors and the risk of abnormal serum potassium level
AU - Joseph Hwang, Y.
AU - Lyu, Beini
AU - Chang, Alex R.
AU - Inker, Lesley A.
AU - Grams, Morgan E.
AU - Shin, Jung Im
N1 - Funding Information: This work was supported by the National Institute of Diabetes and Digestive and Kidney Disease grants R01DK115534 to M.E. Grams (Principal Investigator) and K01DK121825 to J.-I. Shin (Principal Investigator). Funding Information: A.R. Chang reports employment with Geisinger Health System; consultancy agreements with Novartis; reports receiving research funding for a Novo Nordisk Investigator Sponsored Study; reports receiving honoraria from Reata; reports serving as a scientific advisor or member of Reata and Relypsa; and has other interests/relationships with National Kidney Foundation (NKF) grant support from the NKF Patient Network. J.-I. Shin reports receiving research funding from Merck and the National Institutes of Health. L.A. Inker reports consultancy agreements with Diamtrix and Tricidia; reports receiving research funding from the National Institutes of Health, NKF, Omeros, Reata, and Retrophin; reports serving as a scientific advisor or member of Alport’s Foundation, Diametrix, and Goldfinch; and reports serving as a member of the National Kidney Disease Education Program, AKF, and ASN. M.E. Grams reports receiving honoraria from academic institutions for giving grand rounds and ASN for Young Investigator Award; reports serving as a scientific advisor or member of American Journal of Kidney Diseases, CJASN, JASN Editorial Fellowship Committee, NKF Scientific Advisory Board, Kidney Disease: Improving Global Outcomes (KDIGO) Executive Committee, and United States Renal Data System Scientific Advisory Board; reports other interests/relationships with the NKF, which receives funding from Abbvie, Relypsa, and Thrasos; and reports receiving travel support from Dialysis Clinic, Inc. to speak at the annual meeting and KDIGO for participation in scientific meetings and the executive committee. The remaining authors have nothing to disclose.
PY - 2021/7
Y1 - 2021/7
UR - http://www.scopus.com/inward/record.url?scp=85111056728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111056728&partnerID=8YFLogxK
U2 - 10.2215/CJN.02130221
DO - 10.2215/CJN.02130221
M3 - Letter
C2 - 34491898
AN - SCOPUS:85111056728
VL - 16
SP - 1094
EP - 1096
JO - Clinical journal of the American Society of Nephrology : CJASN
JF - Clinical journal of the American Society of Nephrology : CJASN
SN - 1555-9041
IS - 7
ER -